NBE Therapeutics AG. (11/15/18). "Press Release: Dr. Anthony Tolcher Joins the Scientific Advisory Board of NBE Therapeutics". Basel.

	Organisation	NBE Therapeutics AG
	Product	antibody-drug conjugate (ADC)
	Product 2	antibody-drug conjugates (ADC) technology
	Person	Tolcher, Anthony (NEXT-Oncology 201811 CEO + Founder before START (South Texas Accelerated Research Therapeutics))
	Person 2	Grawunder, Ulf (NBE Therapeutics 201610 CEO before 4-Antibody CSO before CEO + founder)

NBE Therapeutics AG, a biopharmaceutical company developing next-generation immune-stimulatory antibody-drug conjugates (iADCs™) for improved cancer therapy, today announces the appointment of Dr. Anthony Tolcher to NBE's Scientific Advisory Board (SAB). Dr. Tolcher is a Board certified Medical Oncologist from San Antonio, TX, U.S.A., with significant experience in performing early-stage clinical trials with Antibody Drug Conjugates (ADCs). Dr. Tolcher was previously co-founder and a leading member of START (South Texas Accelerated Research Therapeutics), managing a network of global clinical trial centers across the U.S., Europe and Asia. Currently, Dr. Tolcher is founder and CEO of NEXT-Oncology in San Antonio, TX, U.S.A, a clinical research organization dedicated to advance highly innovative cancer medicines to first-in-human clinical trials. Dr. Tolcher is a renowned key opinion leader in the field of clinical development of ADCs and advises NBE-Therapeutics on its strategies to advance NBE's late-stage preclinical development pipeline of iADCs™ to early stage clinical validation in cancer patients (phaseI/II clinical trials).

Dr. Tolcher commented: "Having performed a comprehensive review of NBE's late-stage preclinical data for NBE-Therapeutic's iADC programs, and in particular NBE's lead program NBE-002 targeting ROR-1 to treat difficult solid tumors, like triple negative breast cancer (TNBC), sarcoma and lung cancer, I am very excited to support NBE-Therapeutics to advance its iADC programs to the clinic. There are tremendous opportunities of NBE's platform to lead to advancements in the treatment of many cancers and as a combination with current and future immune checkpoint inhibitors.”

Dr. Ulf Grawunder, CEO of NBE Therapeutics commented: “We are extremely excited that Tony joins the Scientific Advisory Board of NBE-Therapeutics. Tony's expertise of translating ADCs to clinical proof-of-concept is very impressive. Tony has been clinical investigator for many ADCs and we are all convinced that Tony's deep clinical experience in the ADC field and his vision how to bring innovative cancer drugs to patients will greatly contribute to the future success of NBE-Therapeutics' iADCs.”

About NBE Therapeutics AG

NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company, founded in 2012 with the vision to develop next-generation, immune-stimulatory iADC products. The products will be advanced to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of iADC development: its patented Transpo-mAb Display™ technology for antibody discovery, its patented SMAC-Technology™ for site-specific payload conjugation of toxins to antibodies and its patented novel ultra-potent anthracycline-based toxin platform. The company is financially backed by the Boehringer Ingelheim Venture Fund, the PPF Bioventure Fund, Novo Holdings and additional private investors.

Contact

Ulf Grawunder
CEO, NBE Therapeutics AG
+41 61 633 2230
ulf.grawunder@nbe-therapeutics.com

Record changed: 2018-11-29